Single institution experience of MRI-guided radiotherapy for thoracic tumors and clinical characteristics impacting treatment duty cycle.

Introduction: MRI-guided radiotherapy (MRgRT) allows for direct motion management and real-time radiation treatment plan adaptation. We report our institutional experience using low strength 0.35T MRgRT for thoracic malignancies, and evaluate changes in treatment duty cycle between first and final MRgRT fractions.

Estimating the risk of brain metastasis for patients newly diagnosed with cancer.

Background: Brain metastases (BM) affect clinical management and prognosis but limited resources exist to estimate BM risk in newly diagnosed cancer patients. Additionally, guidelines for brain MRI screening are limited. We aimed to develop and validate models to predict risk of BM at diagnosis for the most common cancer types that spread to the brain.

Elucidating survival and functional outcomes in patients with primary head and neck malignancies treated in academic versus community settings.

Background: Differences in treatment outcomes between community or academic centers are incompletely understood.

Methods: Retrospective review of head and neck cancer patients between 2010 and 2020 in a rural health region. Kaplan-Meier curves and log-rank tests were used to evaluate survival outcomes, along with bivariate and multivariable Cox proportional hazards models.

Cost-Effectiveness Analysis of Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma.

Background And Purpose: While contrast-enhanced MR imaging is the criterion standard in meningioma diagnosis and treatment response assessment, gallium Ga-DOTATATE PET/MR imaging has increasingly demonstrated utility in meningioma diagnosis and management. Integrating Ga-DOTATATE PET/MR imaging in postsurgical radiation planning reduces the planning target volume and organ-at-risk dose. However, Ga-DOTATATE PET/MR imaging is not widely implemented in clinical practice due to higher perceived costs.